Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study

Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer

(2014) Z. Yu et al.   CLINICAL CANCER RESEARCH

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

(2014) Emmanuel S. Antonarakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)

(2013) Y. Loriot et al.   ANNALS OF ONCOLOGY

Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide

(2013) K. L. Noonan et al.   ANNALS OF ONCOLOGY

Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone

(2013) Andres Jan Schrader et al.   EUROPEAN UROLOGY

Mechanisms of the androgen receptor splicing in prostate cancer cells

(2013) L L Liu et al.   ONCOGENE

Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer

(2012) R. Hu et al.   CANCER RESEARCH

Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines

(2012) Y. Li et al.   CANCER RESEARCH

Sarcopenia During Androgen-Deprivation Therapy for Prostate Cancer

(2012) Matthew R. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

The mutational landscape of lethal castration-resistant prostate cancer

(2012) Catherine S. Grasso et al.   NATURE

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

(2012) Howard I. Scher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

(2012) Charles J. Ryan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer

(2012) John T. Isaacs et al.   PROSTATE

Androgen Receptor Gene Expression in Prostate Cancer Is Directly Suppressed by the Androgen Receptor Through Recruitment of Lysine-Specific Demethylase 1

(2011) Changmeng Cai et al.   CANCER CELL

Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc

(2011) Chih-Pin Chuu et al.   CANCER SCIENCE

Transcription-Induced DNA Double Strand Breaks: Both Oncogenic Force and Potential Therapeutic Target?

(2011) M. C. Haffner et al.   CLINICAL CANCER RESEARCH

Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants

(2011) Elahe A. Mostaghel et al.   CLINICAL CANCER RESEARCH

Abiraterone and Increased Survival in Metastatic Prostate Cancer

(2011) Johann S. de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant

(2010) Shihua Sun et al.   JOURNAL OF CLINICAL INVESTIGATION

Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements

(2010) Michael C Haffner et al.   NATURE GENETICS

Loss of Androgen Receptor-Dependent Growth Suppression by Prostate Cancer Cells Can Occur Independently from Acquiring Oncogenic Addiction to Androgen Receptor Signaling

(2010) Jason M. D'Antonio et al.   PLoS One

Bipolar androgen therapy: The rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer

(2010) Samuel R. Denmeade et al.   PROSTATE

Testosterone replacement in prostate cancer survivors with hypogonadal symptoms

(2009) Robert L. Leibowitz et al.   BJU INTERNATIONAL

Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer

(2009) G. Attard et al.   CANCER RESEARCH

DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer

(2009) Jason M D'Antonio et al.   ENDOCRINE-RELATED CANCER

Phase 1 Trial of High-Dose Exogenous Testosterone in Patients with Castration-Resistant Metastatic Prostate Cancer

(2009) Michael J. Morris et al.   EUROPEAN UROLOGY

A Randomized Phase 1 Study of Testosterone Replacement for Patients with Low-Risk Castration-Resistant Prostate Cancer

(2009) Russell Szmulewitz et al.   EUROPEAN UROLOGY

Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone

(2009) J.P. Michiel Sedelaar et al.   PROSTATE

Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer

(2008) Matthew R. Smith et al.   CANCER

Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance

(2008) S. M. Dehm et al.   CANCER RESEARCH

Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth

(2008) R. B. Montgomery et al.   CANCER RESEARCH

Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer

(2008) R. Hu et al.   CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY

Prolonged control of progressive castration-resistant metastatic prostate cancer with testosterone replacement therapy: the case for a prospective trial

(2007) P. Mathew   ANNALS OF ONCOLOGY